Provet Pharma Private Limited - Due diligence report

A 360° intelligence report on Provet Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …

2009-10-14 Chennai, Tamil Nadu Active Unlisted Active Compliant
Share
PP Provet Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Provet Pharma — 360° Intelligence Report

Generated from MCA filings & public records
93/100
Trust Score
Low Risk

Provet Pharma is assessed as Low Risk with a Trust Score of 93/100. Provet Pharma is an active private limited indian non-government company incorporated in 2009, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 20 Jul 2026 from the latest processed filings. Provet Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
93/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.
  • Externally credit-rated (B+).

Charges position: 1 open (26.03 cr) · 3 satisfied (24.53 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited1 48.0 cr
Others2 48.0 cr
Indian Bank1 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 8 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
MUTHU SELVAN VENGAN 01234567 Director 01/04/2018 6 yrs Approved
SUTHANTHIRAKUMAR SENTHIL 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
9 allotment(s) · 2 transfer(s)

Promoters hold a majority stake - exact percentages are part of the full report.

Key managerial personnel: MUTHU SELVAN VENGAN (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
Operating for 16+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence95/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment74/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 26.03 cr already registered.
  • Compliance record supports lending.
Investor view89/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
25 Apr 2024
Charge satisfied
Others
31 Mar 2022
Share transfer (FY 2022)
1250.00000000 shares to SUTHANTHIRAKUMAR SENTHIL
Share transfer (FY 2022)
1250.00000000 shares to VENGAN MUTHUSELVAN
02 Mar 2022
Securities allotted
250 Debentures - 2.50 cr raised
Charge created
Others - 2.50 cr
09 Feb 2022
Charge satisfied
Others
25 Dec 2021
Charge created
Hdfc Bank Limited - 26.03 cr
25 Sep 2018
Director ceased
SUKAKUMAR PUVI KUMAR
06 Jul 2017
Director ceased
SUKAKUMAR SOMASUNDARAM
04 Jul 2017
Charge satisfied
Indian Bank
07 Mar 2017
Charge created
Others - 16.03 cr
01 Apr 2015
Director ceased
MUTHU SELVAN VENGAN
27 Mar 2015
Securities allotted
125000.00 Equity Shares - 80.00 Lakh raised
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
8 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of B+ from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 9 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Vikas Organics Private Limited U74899DL1992PTC050138 New Delhi, Delhi, India
Medibios U24230MH1995PLC086180 -
Pmc-Group U24299WB2005PTC106272 Hoogly, West Bengal, India
Gg Chemicals And Pharmaceuticals Private Limited U27106PB2002PTC065163 Derabassi, Punjab, India
Sunflag Chemicals Private Limited U74899DL1995PTC074455 New Delhi, Delhi, India
Mega Innovative Crops Private Limited U24239GJ2008PTC053246 Ankleshwar, Gujarat, India
Iscon Surgicals Limited U24232RJ1991PLC005963 Jodhpur, Rajasthan, India
M S Healthcare U24239MH2001PTC130893 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Provet Pharma before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Provet Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Provet Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 93/100, distress signals and MSME payment-delay disclosures - know whether Provet Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Provet Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Provet Pharma an active company?

Provet Pharma has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Provet Pharma financially healthy?

Provet Pharma has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Provet Pharma?

Its overall Trust Score is 93/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Provet Pharma?

Promoters hold a majority stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Provet Pharma have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.

Is Provet Pharma up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Provet Pharma?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.